
    
      Test medication:

        -  Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at
           least a partial remission (PR) after chemotherapy as a single dose for patients with
           baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet
           counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic
           radiolabeled antibodies.

        -  Standard dose chemotherapy consisting of cyclophosphamide, fludarabine and rituximab
           given every 28 days up to the best response (maximum 6 courses).

        -  A prophylaxis for pneumocystis carinii as well as for herpes zoster are needed during
           treatment.

      Main parameters of activity: activity of Yttrium-90 (90Y) ibritumomab tiuxetan after
      cyclophosphamide, fludarabine and rituximab combination.
    
  